Atea's BEM/RZR meets Phase 3 C-BEYOND endpoints in HCV; company secures up to $200M Hercules credit facility

Atea Pharmaceuticals reported Q3 2026 results on November 9, 2026. Its Phase 3 C-BEYOND trial showed bemnifosbuvir/ruzasvir was non-inferior to Epclusa in hepatitis C (SVR 93.91% vs 94.75%), with C-FORWARD data expected in early 2027 and an FDA NDA targeted for mid-2027. Atea also signed a credit facility with Hercules Capital for up to $200 million, drawing $65 million at closing, and continues Phase 1 development of AT-587 for chronic hepatitis E.

09 Nov 2026 · Atea Pharmaceuticals, Inc. AVIR · Company news

Company's press release (SEC filing): Atea Pharmaceuticals, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Atea's BEM/RZR meets Phase 3 C-BEYOND endpoints in HCV; company secures up to $200M Hercules credit facility

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq